https://ijper.in/index.php/IJPER/issue/feed 2026-01-09T08:42:05+00:00 Ms. Payal Kesharwani ijper.editor@gmail.com Open Journal Systems <p><strong>International Journal of Pharmaceutical Education and Research</strong> (IJPER) is an international, peer-reviewed, open access journal devoted to various segments of pharmaceutical sciences. It’s a biannually published journal that publishes quality manuscripts (original research, reviews, short communications, mini-reviews and case reports) relevant to the various fields of Pharmaceutical Sciences.&nbsp;</p> <table border="1" cellspacing="0" cellpadding="5"> <tbody> <tr> <td valign="top" width="265"> <div align="center"><strong>&nbsp;</strong><strong>Starting Year</strong><br>2019</div> </td> <td valign="top" width="301"> <div align="center"><strong>Journal ISSN<br></strong>2582-2152 (Online)</div> </td> <td valign="top" width="234"> <div align="center"><strong>CrossRef DOI Prefix</strong><br>10.37021</div> </td> <td valign="top" width="218"> <div align="center"><strong>Frequency</strong><br>2 Issues/Year (Biannual)</div> </td> </tr> <tr> <td valign="top"> <div align="center"><strong>&nbsp;</strong><strong>Publishing System</strong></div> <div align="center">Open Journal System<strong><br> </strong> (OJS) by Public knowledge Project (PKP)</div> </td> <td valign="top"> <div align="center"><strong>Copyright License Type</strong></div> <div align="center">Creative Common Attribution-NonCommercial 4.0 International<br>(CC BY-NC-SA 4.0)</div> </td> <td valign="top"> <div align="center"><strong>Email</strong></div> <div class="style1" align="center">ijper.editor@gmail.com</div> <div class="style1" align="center">editor@ijper.in</div> </td> <td valign="top"> <div align="center"><strong>Primary Contact</strong></div> <div align="center">+91-7974318397</div> </td> </tr> </tbody> </table> <p>&nbsp;</p> <p><strong>Journal Abbreviation:</strong>&nbsp; <em>Int. J. Pharm. Edu. Res.</em></p> <p><strong>Indexing:</strong>&nbsp; International Journal of Pharmaceutical Education and Research, IJPER is indexed with <a href="https://scholar.google.co.in/citations?user=CEhnT44AAAAJ&amp;hl=en">Google Scholar</a>, <a href="https://www.researchgate.net/journal/2582-2152_INTERNATIONAL_JOURNAL_OF_PHARMACEUTICAL_EDUCATION_AND_RESEARCH_IJPER">ResearchGate,</a> World Cat, <a href="https://cassi.cas.org/publication.jsp?P=DXaT8ZV7yNcyz133K_ll3zLPXfcr-WXfNKTEt1-l894yz133K_ll3zLPXfcr-WXf-9sRQmIIxJMyz133K_ll3zLPXfcr-WXfIY0JLEXX41RsDpuJibhy6A">CAS Source Index (CASSI)</a>,&nbsp;<a href="https://portal.issn.org/resource/ISSN/2582-2152#">ROAD (Directory of Open Access Scholarly Resources)</a>,&nbsp;<a href="http://journalseeker.researchbib.com/?action=viewJournalseekerSearch">Research Bible (Academic Resource Index)</a>, <a href="https://www.sciencegate.app/source/401708839">SCIENCEGATE</a>,&nbsp;<a href="http://olddrji.lbp.world/JournalProfile.aspx?jid=2582-2152">Directory of Research Journals Indexing (DRJI)</a>,&nbsp; Index Copernicus (ICV),&nbsp;Crossref,&nbsp;and many more.</p> <p><strong>Why IJPER?</strong></p> <ul> <li class="show">Global audience with Open and immediate access to all publications.</li> <li class="show">Worldwide dissemination through OJS platform.</li> <li class="show">Prompt and unbiased review process.</li> <li class="show">Indexed with the most important international bibliographic databases.</li> <li class="show">Regular alerts on E-mail</li> </ul> <p><strong>Articles invited for Volume 6, Issue 2.</strong></p> https://ijper.in/index.php/IJPER/article/view/314 2026-01-09T08:17:11+00:00 sunishtha_kalra Kalra sunishtha.kalra279@gmail.com Himanshu Sachdeva Sunishtha.kalra279@gmail.com Govind Singh Sunishtha.kalra279@gmail.com

Traumatic Brain Injury (TBI) remains a significant global health concern, affecting millions of individuals annually and often resulting in devastating neurological consequences. Despite decades of research, effective treatment options for TBI remain limited. This abstract provides an overview of the current state of neuroprotection strategies in TBI, highlighting the transition from experimental bench research to clinical application at the bedside.At the bench level, extensive investigations into the pathophysiological mechanisms of TBI have led to the identification of various potential targets for neuroprotection. These mechanisms include excitotoxicity, oxidative stress, inflammation, and disruption of the blood-brain barrier. Numerous preclinical studies have explored the efficacy of various compounds, including neuroprotective agents, antioxidants, anti-inflammatory drugs, and growth factors, in mitigating TBI-induced damage. Innovative approaches such as stem cell therapy and gene editing techniques have also shown promise in preclinical models.The translation of these promising bench findings to clinical practice has been challenging but is making gradual progress. Clinical trials are being conducted to assess the safety and efficacy of several neuroprotective interventions, including hypothermia, neurotrophic factors, and pharmacological agents, in TBI patients. Advanced neuroimaging techniques, biomarker discovery, and personalized medicine approaches are aiding in patient stratification and treatment optimization.In conclusion, the journey from bench to bedside in the realm of neuroprotection for TBI is marked by significant strides in understanding the underlying mechanisms of injury and the exploration of novel therapeutic avenues. While challenges remain, ongoing research and clinical trials offer hope for improved outcomes and better quality of life for TBI patients in the future.

2026-01-09T08:17:11+00:00 ##submission.copyrightStatement## https://ijper.in/index.php/IJPER/article/view/316 2026-01-09T08:22:13+00:00 Pradyumn Sharma seemaguptaggg@gmail.com Azhar Danish Khan seemaguptaggg@gmail.com Seema Gupta seemaguptaggg@gmail.com

Pelargonium graveolens L'Hér (Geraniaceae), widely referred to as rose-scented geranium, is a perennial aromatic species recognized for its long-standing use in traditional medicine and its substantial economic significance. This review consolidates contemporary findings on the plant’s phytochemical profile, pharmacological properties, and therapeutic relevance. The essential oil and various extracts of P. graveolens are rich in bioactive constituents—particularly monoterpenes such as citronellol, geraniol, and linalool, along with diverse polyphenols—that collectively contribute to a broad array of biological activities, including antioxidant, antimicrobial, anti-inflammatory, antidiabetic, and anticancer effects. Evidence from in vitro and in vivo investigations indicates considerable therapeutic potential; however, clinical validation remains insufficient. This review provides a critical appraisal of the current literature, highlights existing knowledge gaps, and outlines priorities for future research aimed at advancing preclinical insights toward clinical applicability

2025-12-30T00:00:00+00:00 ##submission.copyrightStatement## https://ijper.in/index.php/IJPER/article/view/302 2026-01-09T07:59:50+00:00 Bhagyashri Bhausaheb Randhawan bhagyashrirandhawan@gmail.com

Polymeric nanoparticles (NPs) are tiny particles with a size between 10 and 1000 nm, with the ability to contain or have active substances surface-adsorbed onto the polymeric core. Both nanospheres and nano capsules are under the umbrella of "nanoparticles," which are distinguished by the morphological organisation. For the targeted delivery of medications used to treat a variety of disorders, polymeric NPs have demonstrated considerable promise. We go through the most popular techniques for creating and characterising polymeric NPs, the effectiveness of the active ingredient's connection with the polymeric core, and in vitro release mechanisms in this review. Due to their adaptability and broad range of features, polymeric nanoparticles have recently gained more potential usage as carriers for a variety of pharmaceuticals in therapeutic applications. Due to the drawbacks of conventional pharmacological therapy, there will be a higher risk of unpleasant responses. These days, nanoparticles are becoming more and more significant since they enable activity at specific locations. These nanoparticles enable the precise targeting of different cells or receptors. Cellular absorption and internalisation are both regulated in a number of different ways.

2025-12-30T00:00:00+00:00 ##submission.copyrightStatement## https://ijper.in/index.php/IJPER/article/view/336 2026-01-09T08:39:21+00:00 Anjali Yadav azhardk@gmail.com Seema Gupta azhardk@gmail.com Azhar Danish Khan azhardk@gmail.com

Sisymbrium irio L. (often referred to as London rocket or Khaksi) is an annual herb of the Brassicaceae family and has been traditionally used in the treatment of respiratory conditions like cough, asthma, sore throat, and bronchitis, and in fever, infections, and weakness. Numerous phytochemical and pharmacological studies during the last few decades have supported many of these uses. Phytochemical studies of its seeds and aerial parts identify a diverse array of bioactive metabolites consisting of flavonoids like isorhamnetin, glucosinolates, phenolic acids, alkaloids, sterols, saponins, tannins, and terpenoids. Fatty acid composition of its seed oil features appreciable contents of linolenic, linoleic, oleic, and erucic acids, testifying to both nutritional and medicinal significance. These constituents are responsible for the varying pharmacological activities described for S. irio, which include antioxidant, anti-inflammatory, antimicrobial, anticancer, gastroprotective, and bronchodilatory activities. Experimental evidence indicates that its mode of action is by free radical scavenging, inhibition of inflammatory mediators, and antimicrobial activity through glucosinolate-derived isothiocyanates. The variability of phytoconstituents, combined with new preclinical data, makes S. irio a potential candidate for novel therapeutic compounds. This review synthesizes and critically reviews recent knowledge on its phytochemistry and pharmacological attributes thus summarizes the information for further studies

2025-12-30T00:00:00+00:00 ##submission.copyrightStatement## https://ijper.in/index.php/IJPER/article/view/337 2026-01-09T08:42:05+00:00 Pradeepthi Are pradeepthi.a@gmail.com Shanmugam Vippamakula pradeepthi.a@gmail.com

Neglected tropical diseases (NTDs) and parasitic infections (such as leishmaniasis, malaria, Chagas disease, schistosomiasis) disproportionately impact poor populations worldwide. Existing treatments are beset with issues such as reduced efficacy, toxicity, drug resistance, and compliance issues. This review examines vitamin C (ascorbic acid) as an adjunctive therapy to enhance the efficacy of current antiparasitic drugs based on available preclinical evidence. A comprehensive literature analysis reveals vitamin C’s antioxidant, immunomodulatory, and synergistic activities. It has been evidenced to modulate oxidative stress, enhance drug bioavailability, and bolster host immunity. When co-administered with traditional drugs, vitamin C demonstrated a 30-60% reduction in parasitic burdens, improved survival rates by 15-25%, and reduced organ damage in experimental models. Specific benefits included enhanced macrophage activity in leishmaniasis models, 40-50% reduction in cardiac inflammatory markers in Chagas disease, and improved parasite clearance rates in malaria studies. Its affordability and accessibility make it feasible for implementation in endemic areas. Vitamin C shows considerable promise as an adjunct therapy in NTDs. However, clinical trials are urgently required to establish human efficacy, optimize dosing regimens, and validate safety profiles observed in preclinical studies.

2025-12-30T00:00:00+00:00 ##submission.copyrightStatement##